Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,714.00
(
-1.73%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,073.25
(
-3.88%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: upndown1313 post# 35498

Wednesday, 10/18/2006 5:01:56 PM

Wednesday, October 18, 2006 5:01:56 PM

Post# of 257257
GILD has a non-nucleoside HCV polymerase inhibitor called GS9190. The IND has been filed and phase-1 is expected to start before year-end. This is the first I’ve heard of this program. (I think GILD had kept it under wraps until today.)

The most direct competitor of GILD’s new compound is HCV-796 from VPHM and WYE.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now